When was Altuviiio approved by the FDA?

The U.S. Food and Drug Administration (FDA) approved Altuviiio in 2023 for treating children and adults with hemophilia A. Altuviiio is specifically indicated as a routine prophylactic therapy to lower the frequency of bleeding episodes, as well as an on-demand treatment to control active bleeds, including those occurring during surgery.